Affordable Access

Endocrine abnormalities in patients with endstage renal failure.

Authors
  • Kokot, F
  • Wiecek, A
  • Grzeszczak, W
  • Klepacka, J
  • Klin, M
  • Lao, M
Type
Published Article
Journal
Advances in experimental medicine and biology
Publication Date
Jan 01, 1989
Volume
260
Pages
61–67
Identifiers
PMID: 2560346
Source
Medline
License
Unknown

Abstract

Data presented in this study suggest existence of hyperendorphinism in uraemic patients. This hyperendorphinism may be regarded both as a primary beneficial compensatory mechanism counteracting disturbances of the internal environment, while causing secondary harmful side effects, which contribute to the uraemic state. Erythropoietin treatment of uraemic, haemodialyzed patients is followed by marked endocrine alterations (suppression of plasma levels of STH, ACTH, prolactin, glucagon, aldosterone, cortisol and plasma renin activity, elevation of plasma insulin and atrial natriuretic levels, lack of influence on plasma PTH, CT and AVP). It remains to be clarified whether the erythropoietin induced endocrine alterations are due to correction of the existing anaemia or reflect a specific effect of this hormone.

Report this publication

Statistics

Seen <100 times